End‐of‐life impact of concurrent diabetes mellitus and adrenal insufficiency as immune‐related adverse events in an advanced non‐small cell lung cancer patient

A 49‐year‐old man diagnosed with metastatic non‐small cell lung cancer was treated with immune checkpoint inhibitor (ICI) combination therapy (nivolumab + ipilimumab) as first‐line therapy. During the treatment course, the patient developed ICI‐associated diabetes mellitus and adrenal insufficiency,...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Tomoaki, Takeyasu, Yuki, Yoshida, Tatsuya, Ohashi, Ken, Ohe, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626334/
https://www.ncbi.nlm.nih.gov/pubmed/36195556
http://dx.doi.org/10.1111/1759-7714.14660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626334/
https://www.ncbi.nlm.nih.gov/pubmed/36195556
http://dx.doi.org/10.1111/1759-7714.14660

Ejemplares similares